Navigation Links
Colgate To Develop Anti-Cancer Toothpastes And Mouthwashes

AUSTIN, Texas - Oral care product leader Colgate-Palmolive Company has entered into an alliance with Introgen Therapeutics to market oral health care formulations specifically designed to fight against pre-cancerous //conditions in the oral cavity as well as oral cancer.

Towards this end Colgate purchased $20 million of Introgen shares with exclusive rights over the products that are produced by Introgen. Introgen has a wide range of molecular therapeutics that include tumor suppressors such as p53, mda-7, and FUS1. The company is in an advanced stage of developing INGN 234, a mouthwash designed to deliver the p53 tumor suppressor for the prevention of a pre-cancerous condition called Leukoplakia as well as oral cancer. David G. Nance, Chief Executive Officer of Introgen was understandably pleased with the lucrative agreement.

We believe that repair of damaged cells and safe elimination of malignant or pre-malignant cells from the mouth could represent important therapies for dentists, oral health professionals and oncology specialists to prevent and treat oral diseases, he said.

Oral cancer is fast emerging as one of the leading cancers n the world thanks to the killer called Tobacco. Smoking and other factors like chronic trauma do play a large part, but tobacco remains the number 1 culprit. Molecular therapies are emerging technologies that have the potential to fight cancers on the molecular level, giving the patient a better chance of survival and sparing the trauma of chemotherapy as well as radiation therapy. This is the first time that an attempt has been made to deliver a therapeutic agent against oral cancer
'"/>




Page: 1

Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
3. Risk Of Developing Arthritis
4. Developing HIV fighter
5. Missing Protein In Cancer Development
6. Tomatoes Might Inhibit the Development Of Prostate Cancer
7. Antibiotics Found To Increase The Risk Of Developing Breast Cancer
8. The Effectiveness Of Cancer Drug In Women At Risk Of Developing Cancer
9. Men Who at Risk Of Developing Prostate Cancer
10. Identifying The Risks Of Developing Schizophrenia
11. Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... (CDC), rising prescription opioid overdose deaths now claim the lives of 62 Americans ... civil case filings against drug manufacturers, distributors, pharmacies and prescribers by more than ...
(Date:4/24/2017)... ... , ... Rod Burkett, CEO of Gardant Management Solutions, was recently featured in ... the forefront of Gardant since it was founded in 1999. His drive and inquisitive ... more than 40 new senior living communities. With his leadership, Gardant has grown to ...
(Date:4/24/2017)... ... 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa on May 20 and ... educational and exciting 2-day program. , An attendee at a recent PAINWeekEnd said, ... patients” about the course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, ...
(Date:4/24/2017)... NY (PRWEB) , ... April 24, 2017 , ... ... 72 countries clearly shows that over the last decade, student well-being has seriously ... all the boxes of formal education, join the Islamic State to turn the ...
(Date:4/24/2017)... ... ... “The Saint with Trin, and Omega Station”: a triple feature offering nonstop ... published author, Chris Jackson. Chris Jackson grew up in Abilene, Texas. He ... District teaching English. He is heavily involved in the youth group of his local ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... that it will be participating in the Deutsche Bank ... Hotel in Boston, Massachusetts on ... 11:20 a.m. Eastern Time. A live webcast ... Investor Relations website at http://investor.zimmerbiomet.com .  The webcast ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
Breaking Medicine Technology: